跳至主要内容
临床试验/NCT05526404
NCT05526404已完成不适用

Mobile Application Based Lactulose Titration for Prevention of Hepatic Encephalopathy

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2022年9月14日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Mayo Clinic
入组人数
50
试验地点
2
主要终点
Achievement of daily stool goal

研究概览

简要总结

This study is being done to assess the safety and efficacy of using mobile application-based Bristol stool scale to titrate lactulose in prevention episodes of hepatic encephalopathy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ability to provide written, informed consent.
  • Currently taking lactulose daily for prevention of hepatic encephalopathy.

排除标准

  • Recent change in dosing of opioid medication.
  • Previous Colorectal Surgery.
  • Active diarrheal illness.
  • Lack of smartphone or other smart device at home.

结局指标

主要结局

Achievement of daily stool goal

时间窗: 4 weeks

Number of subject to achieve daily stool goal, determined if use of the mobile application leads to improved rates of meeting daily stool goal (3-4 stools per day of Bristol Stool Scale 3-4)

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Douglas (Doug) A. Simonetto

Principal Investigator

Mayo Clinic

研究点 (2)

Loading locations...

相似试验

Prevention of Hepatic Encephalopathy With Mobile... | 临床试验